Home > Insider Trading > Filing (0001144204-13-053925)

Filing Details

Accession Number:: 0001144204-13-053925
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-10-03 21:30:57
Reporting Period:: 2013-10-01

Filing Date:: 2013-10-03
Accepted Time:: 2013-10-03 21:30:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1270073	Intercept Pharmaceuticals Inc	ICPT	Pharmaceutical Preparations (2834)	223868459

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1559570	David Shapiro	C/O Intercept Pharmaceuticals, Inc. 18 Desbrosses Street New York NY 10013	Cmo & Evp - Development	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-10-01	1,622	$0.00	5,888	No	4	M	Direct
Common Stock	Acquisiton	2013-10-02	3,750	$10.40	9,638	No	4	M	Direct
Common Stock	Disposition	2013-10-02	1,973	$72.02	7,665	No	4	S	Direct
Common Stock	Disposition	2013-10-02	1,177	$73.02	6,488	No	4	S	Direct
Common Stock	Disposition	2013-10-02	600	$74.60	5,888	No	4	S	Direct
Common Stock	Disposition	2013-10-02	642	$73.10	5,246	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2013-10-01	1,622	$0.00	1,622	$0.00
Common Stock	Options to Purchase Common Stock	Disposition	2013-10-02	3,750	$0.00	3,750	$10.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
14,603			No	4	M	Direct
60,288		2018-04-01	No	4	M	Direct

Footnotes

The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 20, 2013.
Conversion of restricted stock units ("RSUs") to shares of common stock on a one-for-one basis.
On November 16, 2012, the reporting person was granted 25,961 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 6.25% of the shares underlying the RSUs, became vested on October 1, 2013, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares underlying the RSUs will vest pro rata on a quarterly basis from January 1, 2014 through January 1, 2016, subject to the terms and conditions of the award and the 2012 Plan.
All shares underlying this option have vested.
This transaction was executed in multiple trades at prices ranging from $72.00 to $72.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $73.00 to $73.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $73.00 to $73.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.